Clinical Trials Aimed at HIV Cure or Remission: New Pathways and Lessons Learned
Source : https://pubmed.ncbi.nlm.nih.gov/37856845/
The landscape of clinical trials for HIV cure and remission has evolved considerably over the past 10 years.
Pharmaceutical agents aimed at enhancing the function of immune effector cells or sensitizing latently infected cells to undergo apoptosis could be important adjuvant therapies in future HIV cure strategies.
Tolerability of Bictegravir/Tenofovir Alafenamide/Emtricitabine Versus Dolutegravir/Lamivudine as Maintenance Therapy in a Real-Life Setting
Source : https://academic.oup.com/jac/advance-article-abstract/doi/10.1093/jac/dkad338/7329255
While both the burden of therapy and the individual drugs in bictegravir/tenofovir alafenamide/emtricitabine (BIC/TAF/FTC) and dolutegravir...
Switching to dolutegravir/lamivudine or bictegravir/tenofovir alafenamide/emtricitabine showed no difference in risks of overall or toxicity-related discontinuations or in the profile of adverse events leading to discontinuation.
Life expectancy after 2015 of adults with HIV on long-term antiretroviral therapy in Europe and North America: a collaborative analysis of cohort studies
Source : https://www.thelancet.com/journals/lanhiv/article/PIIS2352-3018(23)00028-0/fulltext
For people with HIV on ART and with high CD4 cell counts who survived to 2015 or started ART after 2015, life expectancy was only a few years lower than...
Interpretation: For people with HIV on ART and with high CD4 cell counts who survived to 2015 or started ART after 2015, life expectancy was only a few years lower than that in the general population, irrespective of when ART was started. However, for people with low CD4 counts at the start of follow-up, life-expectancy estimates were...
Temsavir blocks the immunomodulatory activities of HIV-1 soluble gp120
Richard et al. provide extensive evidence suggesting that treatment with the HIV-1 attachment inhibitor temsavir can have beneficial effects that extend beyond viral neutralization, notably by preventing elimination of uninfected...
Conclusions/Relevance: Temsavir prevents shed gp120 from interacting with uninfected bystander CD4+ cells, protecting them from ADCC responses and preventing a cytokine burst. Mechanistically, this depends on temsavir’s capacity to prevent soluble gp120-CD4 interaction, to reduce gp120 shedding, and to alter gp120 antigenicity. This...
Fostemsavir and ethinyl estradiol drug interaction: Clinical recommendations for co-administration - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36372442/
Applying the results of Study 206279 and other relevant ARV-contraceptive studies, we recommend that when co-administering fostemsavir with combined oral contraceptives (COCs) and other oestrogen-based therapies, EE dose should not...
Conclusions: Applying the results of Study 206279 and other relevant ARV-contraceptive studies, we recommend that when co-administering fostemsavir with combined oral contraceptives (COCs) and other oestrogen-based therapies, EE dose should not exceed 30 μg or equivalent, and caution is advised in the case of individuals with risk factors...